

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number
WO 03/015802 A1(51) International Patent Classification⁷: A61K 35/14

Apartment, Apkujong-dong, Kangnam-ku, 135-785 Seoul (KR).

(21) International Application Number: PCT/KR02/01552

(22) International Filing Date: 14 August 2002 (14.08.2002)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
2001/49147 14 August 2001 (14.08.2001) KR
2001/49148 14 August 2001 (14.08.2001) KR

(71) Applicant (for all designated States except US): MEDI-POST, CO., LTD. [KR/KR]; 3rd Fl., West Bldg., Doosan Technical Center, 39-3, Sungbok-dong, Yongin-si, 449-795 Kyungki-do (KR).

(71) Applicant and

(72) Inventor: HA, Chul-Won [KR/KR]; 1-306, Misung

(72) Inventors; and

(75) Inventors/Applicants (for US only): YANG, Yoon-Sun [KR/KR]; 20-202, Woosung Apartment, Jamsil 7-dong, Songpa-ku, 138-798 Seoul (KR). YANG, Sung-Eun [KR/KR]; 102-1203, Hansol Apartment, 5, Samsung-dong, Kangnam-ku, 135-090 Seoul (KR).

(74) Agents: PARK, Seung-Moon et al.; DARAE Law & International Patent, 18th Floor, Kangnam Building, 1321-1, Seocho-dong, Seocho-ku, 137-070 Seoul (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,

[Continued on next page]


(54) Title: COMPOSITION FOR TREATMENT OF ARTICULAR CARTILAGE DAMAGE



(57) Abstract: The present invention is related to a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention is characterized by that it is composed of cellular components separated, proliferated, and/or differentiated from the umbilical cord blood and their media, or of the above cellular components, their media, and biocompatible polymers. Compared to the conventional cells used for the treatment of articular cartilage damage, cellular components of the composition of the present invention have very superior ability of proliferation and differentiation and more easy to be collected and acquired. And the polymers of the composition of the present invention have one or more characteristics among the biocompatibility, biodegradation property and possible ability to serve to enhance nutrition of cells and possible ability to enhance formation of intercellular substrate as well as the mechanical strength and flexibility to the degree which is proper for cellular transplantation and generation of cartilage tissues.

US Appl No 10/526,753
IDS Ref 6

BEST AVAILABLE COPY



WO 03/015802 A1



SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

Published:

- *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COMPOSITION FOR TREATMENT OF ARTICULAR CARTILAGE DAMAGE

BACKGROUND OF THE INVENTION

5

Field of the Invention

The present invention is related to a composition for the treatment of articular cartilage damage or loss or defect.

10

Description of the Prior Art

The articular cartilage damage induces pain in the articular region, fault of the articular movement, etc., and lowers the quality of life as well as productivity. Particularly, it is difficult to treat completely the articular cartilage damage since the natural healing power is very low and it is connected to the damage to the entire articulation as it is progressed continuously once it occurs.

15

The methods of treatment of articular cartilage damage developed up to the present time include chondroplasty, osteochondral transplantation, autologous chondrocyte transplantation, etc.

Chondroplasty is the most generally used method among the above-described methods. The arthroscopic operation which is the representative method is a method in which diagnosis and operation may be performed simultaneously while magnifying and observing inside of the articulation through a TV monitor by inserting an arthroscope, on which a small-sized camera is mounted, into the articular cavity through a small hole of less than 1 cm.

20

The above method is advantageous in that it is possible to reduce pain and

25

burden of a patient since it is not necessary to have a direct incision of articulation and it is possible to cure immediately after minor damages to tissues are observed through the arthroscope. However, this chondroplasty is not satisfactorily effective in view of its functional aspects since the fibro-cartilage, not hyaline cartilage that is
5 necessary for the articulation actually, is produced mainly.

In the meantime, osteochondral transplantation is a method of producing hyaline cartilage by collecting both of the cartilage and sub-cartilage portions produced already in the normal section of a patient and transplanting them in the damaged cartilage section by making holes properly. This method has been
10 successful in some patients. However, this method may not be said to be a perfect treatment method because of a problem of having cracks between the transplanted portion and original tissues, and is not a general method in that it may be applied to only the patients who are able to be subject to autologous transplantation. And the above method may not be operated if the damaged portion is large since the donated
15 portion is limited, and it is likely that complications occur in the donated portion. Also, the process of operation is comparatively complicated, and sometimes it is not possible to perform arthroscopic operation. In other words, the above method has weaknesses such as a new pain in the donated portion and may incur complications such as a slow rehabilitation including pain, fracture, bleeding, and scar after
20 operation.

Autologous chondrocyte transplantation that has been started to be employed recently is a method of filling the cartilage portion damaged by proliferation of these cells by obtaining chondrocytes from cartilage tissues collected from the normal portion of a patient, culturing and growing them as much as they are needed
25 externally, securing a space by using periosteum and injecting them to the damaged

portion of cartilage along with the culture medium.

Compared to the osteochondral transplantation method in which already produced cartilage tissues are injected to the damaged portion, there is a more possibility of reproducing hyaline cartilage as the transplanted portion is fused
5 comparatively well with the normal portion since the damaged portion is filled with transplanted chondrocytes as they are proliferated directly in the damaged portion. However, there are still pain, aftereffects, and economical burden of a patient eventually due to the operation of twice and the process of operation is also complicated and difficult since it is necessary to perform operation when collecting
10 chondrocytes and when transplanting those cultured externally are transplanted to the portion of articular cartilage damage.

And there are problems with chondrocytes in that it takes a considerable amount of time until as much as the cells that are necessary for transplantation during external culturing of cells are obtained as the proliferation and growth of the cells
15 collected are not active since the chondrocytes collected are obtained from fully grown adults in most cases; the treatment itself could not be accomplished if the cells lose the ability to proliferate at all; and the form of expression of cells is changed since chondrocytes are cultured externally. And it is of concern that the life of cartilage made by culturing again fully grown cells would not be long. And in case
20 of the second operation, complications such as pain, scar, etc. after operation are inevitable since it is necessary to perform a serious incision since no arthroscopic operational methods have been developed yet.

It has been reported that there has been a method of obtaining mesenchymal stem cells (MSCs) that are precursor cells of chondrocytes and osteoblasts from
25 mesenchymal tissues such as autologous bone marrows, muscles, skin, etc.,

proliferating them ex vivo, and injecting them into the portion of articular cartilage damage together with polymers.

It is shown that the cell proliferation ability in the method of treatment of cartilage damage by using mesenchymal stem cells obtained from grown individuals as described in the above is somewhat higher than that of the autologous chondrocyte transplantation method since more undifferentiated cells are obtained and cultured ex vivo. However, the above-described method still shows a weak ability to proliferate cells for the treatment of various ways of cartilage damage fully. Also, the above-described method is required to have a difficult process of collection of bone marrows, and is limited in that construction of an infrastructure such as bone marrow storage banks, etc. is weak.

As described in the above, the methods of treatment of articular cartilage damage developed up to the present time have been problematic in view of their operational processes and effects.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide a composition for the treatment of articular cartilage damage or loss or defect composed of cellular components separated, proliferated, and/or differentiated from the umbilical cord blood, and biocompatible polymers that can have superior effects of treatment of articular cartilage damage through relatively simple operations.

The composition for the treatment of articular cartilage damage of the present invention is characterized by that it is composed of cellular components separated, proliferated, and/or differentiated from the umbilical cord blood, and their

media. Another composition for the treatment of articular cartilage damage or loss or defect of the present invention is characterized by that it is composed of the above cellular components, their media, and biocompatible polymers. Still another composition for the treatment of articular cartilage damage or loss or defect of the present invention is characterized by that it is composed of cellular components
5 separated or differentiated from the umbilical cord blood, and biocompatible polymers.

The cellular components of the composition for the treatment of articular cartilage damage or loss or defect of the present invention are one or more cellular
10 components such as mesenchymal stem cells and/or mesenchymal stem/progenitor cells separated and/or cultured from the umbilical cord blood, precursor cells that are differentiated from the above mesenchymal stem cells and/or stem/progenitor cells, chondrocytes and/or osteoblasts that are differentiated from the above umbilical cord blood-derived mesenchymal stem/progenitor cells.

15 In the composition for the treatment of articular cartilage damage of the present invention, the umbilical cord blood which is the originating tissue of cellular components is defined to be the blood collected from the umbilical vein connecting placenta and fetus.

Among the cellular components of the composition for the treatment of
20 articular cartilage damage of the present invention, mesenchymal stem cells separated from the umbilical cord blood may be differentiated into mesenchymal tissues such as bones, cartilage, fatty tissues, muscles, tendon, etc. under proper conditions for differentiation since they are multipotent contrary to typical stromal cells of bone marrows. Also, mesenchymal stem cells originated from the umbilical
25 cord blood are the cells that may be proliferated under proper conditions without

being differentiated into specific cells or tissues since they have the ability to self-renewal.

Among the cellular components of the composition for the treatment of articular cartilage damage of the present invention, precursor cells include all those
5 that may be obtained during the process of differentiation of mesenchymal stem cells of the umbilical cord blood into chondrocytes or osteocytes, chondroblasts, osteoblasts, etc. among the cells originated from mesenchymal stem cells of the umbilical cord blood.

The cellular components of the composition for the treatment of articular
10 cartilage damage of the present invention may have a much superior ability to proliferate and differentiate since they are the cells originated from younger cells compared to the cells originated from cells including mesenchymal stem cells separated from adult tissues such as bone marrows, muscles, skin, etc..

In the collection and acquisition of originating tissues of the cellular
15 components of the composition for the treatment of articular cartilage damage of the present invention, it is much easier to collect the cellular components than to collect cells from adult tissues such as bone marrows, etc. that require for operative procedures.

Moreover, it is easy to find a donor for the umbilical cord blood since
20 banking or storing of umbilical cord blood is more feasible at birth and the stored umbilical cord blood can be used easily after thawing. Routine storing of bone marrow like umbilical cord blood is impossible.

And since the cellular components of the composition for the treatment of articular cartilage damage of the present invention are the cells of which major
25 histocompatibility antigen HLA-DR (Class II), which is the most important cause of

rejection reaction in interpolation or organ transplantation, is not expressed, the autologous umbilical cord blood as well as allogenic umbilical cord blood may be used in that it is possible to avoid bringing about or minimize immune reactions such as rejection reaction, etc. that may be the problem of the conventional transplantation operation.

The media of the composition for the treatment of articular cartilage damage of the present invention is for suspending cellular components. Generally used cell culture media such as McCoy's 5A media (Gibco), Eagle's basal media, CMRL media, Glasgow minimum essential media, Ham's F-12 media, Iscove's modified Dulbecco's media, Liebovitz' L-15 media, RPMI 1640 media, etc. may be used.

In the present invention, if necessary, one or more secondary components may be added to the cell culture media. That is, one or more components selected from the sera of a fetal calf, horse, human, etc.; antibiotics such as Penicillin G, gentamycin, streptomycin sulfate, etc. for preventing contamination of microorganisms; antifungal agents such as amphotericin B, nystatin, etc. may be used.

Biocompatible polymers of the composition for the treatment of articular cartilage damage of the present invention are characterized by having one or more characteristics among the biocompatibility, biodegradation property and ability to enhance nutrition of cells and ability to enhance formation of intercellular substrate. Biocompatible polymers of the composition for the treatment of articular cartilage damage of the present invention have the semi-solid or gel-like property to the degree that is similar to that of ointments or pastes as well as the mechanical strength and flexibility to the degree that are proper for cellular transplantation and regeneration of cartilaginous tissues or bone.

Accordingly, the composition for the treatment of articular cartilage damage of the present invention is able to accelerate proliferation and differentiation of chondrocytes that are transplanted together as it is located at the damaged region continuously while maintaining a constant shape once it is transplanted and seeking for convenience in operation since its shape may be changed readily to conform to various 3-dimensional geometry that may be shown in the damaged region of cartilage.

Biocompatible polymers that may be used for the composition for the treatment of articular cartilage damage of the present invention may be one or more components selected from natural polymers such as proteins, polysaccharides, etc.; synthetic polymers comprised of hydroxy acids or their derivatives; and organic polymers forming the 3-dimensional scaffold or lattice structure according to chemical binding and their derivatives and transformed compounds. For example, the proteins among natural polymers include fibrin, gelatin, and collagen; saccharides among natural polymers include hyaluronic acid, etc.; synthetic polymers include polyphosphazine, polyacrylate, polyglactic acid, and polyglycolic acid; and organic polymers include pluronic acid, alginic acid and its salts, etc.

It is possible to promote the mechanical strength and flexibility of the composition for the treatment of articular cartilage damage of the present invention by adding the chitosan fiber.

If a polymer is used singly in the present invention, it is possible to adjust its concentration according to the molecular weight and characteristics of each polymer component. The final content of pluronic acid after it is mixed with cells when it is used singly is 30%, and it is preferable to make the final content of hyaluronic acid 3-4% after it is mixed with cells when it is used alone.

When using polymers mixedly in the present invention, it is preferable to use those that are made by mixing them in such a way that the final content of pluronic acid after it is mixed with cells is 15-30% and the final content of hyaluronic acid is 2-4%.

5 If the chitosan fiber is added to the mixed polymer of the above pluronic acid and hyaluronic acid in the present invention, it is preferable to add and mix the same amount of the chitosan fiber to and with the above mixed polymer.

Illustrated below are the method of manufacture of the composition for the treatment of articular cartilage damage and the method of treatment of articular
10 cartilage damage using the above of the present invention.

The method of manufacture of the composition for the treatment of articular cartilage damage of the present invention is comprised of the steps of collection of the umbilical cord blood; separation, culturing, and/or differentiation of mesenchymal stem cells from the umbilical cord blood; and mixing those
15 mesenchymal stem cells and polymers. Each step is further described in detail as follows:

In the step of collection of the umbilical cord blood, in case of the normal vaginal delivery, the umbilical cord blood is collected from the umbilical vein that is extracted fully to the outside in a state that the placenta remains in the uterus after
20 childbirth, or from the umbilical vein in a state that the placenta is extracted fully from the uterus also after childbirth in case of cesarean section.

When collecting the umbilical cord blood from the umbilical vein extracted fully to the outside of the uterus after childbirth in the present invention, it is collected from the umbilical vein connecting the placenta and fetus after an infant is
25 born according to aseptis, where both methods of collecting the umbilical cord blood

before the placenta is removed in the uterus after childbirth and of collecting the umbilical cord blood externally after the placenta is removed may be used. After the umbilical vein is secured, the umbilical cord blood is collected in a collection bag containing an anticoagulant by using collection needles.

5 All conventional methods including that in Korean Patent Application No. 10-2002-0008639, and those in Pittinger MF, Mackay AM, et al., Science 1999; 284: 143-7, Lazarus HM, Haynesworth SE, et al., Bone Marrow Transplant 1995; 16: 557-64 may be used for the method of separation and culturing of mesenchymal stem cells and mesenchymal stem/progenitor cells from the umbilical cord blood collected
10 as described in the above. Among them, an example is described as follows:

Mononuclear cells are separated through centrifugal separation of the umbilical cord blood and washed several times in order to remove foreign materials. If they are plated and cultured in a culture dish and/or flask and/or other container after they are washed, cells are proliferated with forming monolayer. Among them,
15 mesenchymal stem cells and/or stem/progenitor cells are those of which shape observed through a inverted microscope is homogeneous and that are proliferated in the form of colonies of long cells of the spindle shape. Thereafter, when the cells are grown to be confluent, sub-culturing is performed in order to have the cells proliferated until the necessary number of cells is reached.

20 Mesenchymal stem cells and stem/progenitor cells originated from the umbilical cord blood of the present invention may be used directly for the operation or after they go through the differentiation process.

As to the method of differentiation of mesenchymal stem cells originated from the umbilical cord blood of the present invention, any proper method in which
25 desired cells may be obtained may be selected and used among conventionally used

methods (Barry F, Boynton RE, et al., Exp cell Res 2001; 268: 189-200, Jaiswal N, Haynesworth SE, et al., J Cell Biochem 1997; 64: 295-312). Among them, one example is described as follows:

While culturing cells originated from the umbilical cord blood in proper
5 chondrogenic differentiation media or osteogenic differentiation media, to what degree differentiation is progressed is confirmed through the measurement of expression of enzymes, immune expression type analysis, histochemical stain, histimmunologic stain, molecular biological examination, or cellular medium analysis. Mesenchymal stem cells thus manufactured and the cells differentiated
10 from them may be used directly for the operation, or may be kept frozen, thawed when necessary, and proliferated again to be used.

The method of keeping the cells of the present method frozen is performed according to the widely known method (Doyle et al., 1995). The medium used for keeping frozen is composed of 10-20% FBS (fetal bovine serum), 10% DMSO
15 (dimethylsulfoxide), and 5-10% glycerol. The cells are suspended in such a way that about 1×10^6 to 5×10^6 cells exist in 1 ml of the above medium.

The above suspension of cells is distributed into glass or plastic amples for low-temperature freezing, sealed, and put into a controlled rate freezer with the conditions for temperature adjusted in advance. It is preferable to use a freezing
20 program offering the change of temperature of $-1^\circ\text{C}/\text{min}$ when freezing the cells since it is possible to reduce damage to the cells when they are thawed thereafter. Once the temperature of amples reaches -180°C , they are transferred to a liquid nitrogen storage tank. The cells kept frozen may be stored for several years. Whether the viability of the cells is maintained should be checked periodically at
25 least every five years. When thawing the cells kept frozen, the amples are moved

promptly to a water tub of which temperature is adjusted to 37°C from the liquid nitrogen storage tank. The content thawed in the amples is moved immediately to a culturing container having the medium containing 10% FBS and 5% ES in the sterilized state. The density of cells on the culturing medium is adjusted to have
5 about 3×10^5 to 6×10^5 cells existed per ml of the medium. Whether the cells are proliferated is checked with a inverted microscope every day. When a proper density of cells is reached, the cells are transferred to a new medium for sub-culturing.

The cells cultured as described in the above are transplanted directly to the
10 region of articular cartilage damage in the state suspended on a proper medium or after they are mixed with polymers. In other words, a method of injection of the cells suspended on the medium to a space made of appropriate biomembranes such as periosteum, etc. of the region of cartilage damage in a state not mixed with polymers, sealing them so that the suspension of cells is not leaked out through the
15 cracks of this periosteum, and suturing all of incised sections of operation may be used. Or the above cells may be used by mixing them with appropriate polymers along with the medium and making them in a state which is similar to that of ointments or pastes. In all cases, it is preferable to adjust the concentration of cells contained finally in the composition of the present invention to have 1×10^6 to 5×10^7
20 cells existed in 1 ml. The amount of administration of the composition of the present invention may be increased or reduced according to the size of the portion of articular damage to be cured, and generally, it is preferable to use about 2 ml in case of knee joints of adults having the size of about 2 cm².

In the method of treatment of the articular cartilage damage using the
25 composition of the present method, the articular cartilage portion to be operated is

observed preferably through the arthroscopic operation, the damaged portion is prepared to facilitate the operation, the composition of the present invention is applied to the damaged portion, and whether it is positioned stably is confirmed preferably by using an arthroscope. The form of the composition of the present invention may be formulated to fit into the damaged portion in advance before it is applied to the lesion or changed to fit after it is applied into the damaged portion.

As described above, the method of treatment of the articular cartilage damage using the composition of the present invention may secure the convenience of the procedures and reduce pain, sequelae and morbidity of a patient since the damaged cartilage may be cured sufficiently through the arthroscopic operation, whereas conventional cell plantation methods require for the operation of several times.

BRIEF DESCRIPTION OF THE DRAWINGS

15

The foregoing and other objects, aspects, and advantages will be better understood from the following detailed description of a preferred embodiment of the invention with reference to the drawings, in which:

Figures 1a and 1b are the diagrams in which the viscosity and strength of a polymer manufactured by mixing pluronic acid and hyaluronic acid, and that manufactured by mixing the chitosan fiber, pluronic acid, and hyaluronic acid are confirmed;

Figures 2a and 2b are the diagrams showing the results of treatment of the portion of articular cartilage damage of rabbits by using the composition of the present invention; and

Figures 3a and 3b are the diagrams showing the amplified portion of cartilage produced newly by the composition of the present invention.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT OF THE INVENTION

5

Hereinafter, the present invention is illustrated in more detail in a preferred embodiment of the invention. However, the scope of the present invention is not limited by that preferred embodiment, and it could be changeable for human application.

10

Referring now to the drawings, illustrated in the following preferred embodiment are the methods of manufacture of the composition of the present invention and of treatment of the articular cartilage damage using the above.

Firstly, cellular components are separated and cultured as follows in order to manufacture the composition of the present invention:

15

Mononuclear cells are separated through centrifugal separation of the umbilical cord blood and washed several times in order to remove foreign materials. If they are plated and cultured in a culture dish and/or flask and/or other container after they are washed, cells are proliferated with forming monolayer. Among them, mesenchymal stem cells and/or stem/progenitor cells are those of which shape observed through a inverted microscope is homogeneous and that are proliferated in the form of colonies of long cells of the spindle shape. Thereafter, when the cells are grown to be confluent, sub-culturing is performed in order to have the cells proliferated until the necessary number of cells is reached.

20

Mesenchymal stem cells and/or stem/progenitor cells of the umbilical cord

25

blood obtained as described in the above are treated with trypsin, washed, suspended on a DMEM medium, and prepared for so that they may be mixed with the polymer in subsequent steps.

Secondly, for the manufacture of the composition of the present invention, polymers are prepared as follows and chemical, biological and/or mechanical properties of polymers are confirmed by performing experiments confirming their chemical, biological and/or mechanical strength in advance.

In order to confirm the mechanical strength according to the concentration or addition or reduction of the components comprising polymers, a polymer containing 30% of pluronic acid finally, a polymer containing 4% of hyaluronic acid finally, a polymer containing hyaluronic acid of each different concentration while containing 15% of pluronic acid finally, and a polymer containing the mixture of the above pluronic acid and hyaluronic acid and further containing the same amount of the chitosan fiber are prepared, in which the final concentrations of hyaluronic acid are 0.5%, 1.0%, 1.5%, 2.0% and 4.0%, respectively.

Each polymer is prepared by mixing the above components and whether each has the proper/appropriate property is evaluated.

As a result, as shown in Figure 1a, a fairly good mechanical strength is shown in case of the polymer containing hyaluronic acid of each different concentration while containing 15% of pluronic acid finally. But it is seen that the mechanical strength is lowered as the concentration of hyaluronic acid is lowered. Particularly, it is observed that the polymer flows down along the wall of the tube if the tube is held upside down when less than 0.5% of hyaluronic acid is contained finally as the mechanical strength is lowered significantly.

On the other hand, the polymer containing the mixture of the above pluronic

acid and hyaluronic acid and additionally the same amount of the chitosan fiber shows the flexibility of the degree which is good to change the shape when it is applied to the damaged region while maintaining the mechanical shape irrespective to the amount of hyaluronic acid. The polymer containing 30% of pluronic acid
5 finally also shows proper mechanical strength and flexibility.

Accordingly, it is possible to select a polymer having the appropriate strength and flexibility to the degree which is proper for applying to the treatment of the region of cartilage damage and its mixed composition.

Thirdly, in order to manufacture the composition of the present invention,
10 among the polymers manufactured in the above, for example, a polymer containing 30% of pluronic acid finally is selected, of which 0.3 g is mixed with about 0.9 ml of the DMEM medium sufficiently. Thereafter, the suspension of cells in the first step in which 1×10^7 cells are contained is concentrated in terms of centrifugal separation, the supernatant is discarded, and the polymer made in the second step is put into the
15 cell portion only. A proper amount of the medium is then added to the above to make the final volume of 1 ml. That is, the composition for the treatment of articular cartilage damage of the present invention is manufactured to include 30% (0.3 g) of the polymer and 1×10^7 cells in 1 ml of the medium. If the amount becomes greater, they are mixed at the same ratio.

20 Fourthly, the articular cartilage damage is treated by using the composition for the treatment of articular cartilage damage of the present invention.

In order to design models for the articular cartilage damage, a healthy rabbit is selected and proper amounts of ketamine(35mg/kg) and xylazine(5mg/kg) according to its body weight are injected intramuscularly. After it is confirmed that
25 the anesthesia of the rabbit is completed fully, the knee joints of both legs are shaved

and fixed with an adhesive plaster while maintaining the supine posture. Both knee joints are disinfected with betadine, their locations are confirmed by palpation with fingers, after which the inside of the joint is observed by reaching the inside of knee joints through the paramedian approach along the incision line passing through the upper and lower portions of knee joints and inner side of the knee cap and bending the knee joints while pushing the knee cap toward the outer side.

After it is confirmed that there are no particular pathologic findings, a centralizing dimple is made at a position 4 mm above the front upper end of the central interchondylar notch of the distal femur with a sharp-pointed gimlet and a hole having the diameter of 3 mm and depth of 3 mm is made centering around the scar with a drill. A punch having the diameter of 3 mm may be used for the same region, and the full thickness cartilage defect is created. The damaged region is observed 3-4 months after the cartilage damage is induced as in the above. And it is confirmed that the damaged region of cartilage is not cured by itself.

In the meantime, 0.25 ml of the composition of the present invention manufactured in the third step is injected and pushed into the damaged region of cartilage of a rabbit by using a syringe.

Thereafter, the knee cap is returned to its original position, soft tissues around the knee cap are repaired with absorbable sutures, and the skin is closed with non- absorbable sutures. The leg on the opposite side is regarded to be a control group, into which only biodegradable polymers are applied.

After it is confirmed that the rabbit regains consciousness from anesthesia, it is allowed to move freely, and antibiotics are administered to it in order to prevent infection after the operation until the next day. After 11 weeks, sections of the articular cartilage region of each rabbit which were subject to damage and treated are

obtained and inspected for newly formed cartilage. The results of comparison are shown in Figures 2a and 2b.

As shown in Figures 2a and 2b, the total thickness of repaired layers produced newly after the composition of the present invention is applied is shown to
5 be more than twice greater (Figure 2b) than that when only the polymer is applied (Figure 2b).

Figures 2a and 2b are amplified and shown in Figures 3a and 3b in order to compare the property of newly formed cartilage repair tissue. As shown in Figures 3a and 3b, cartilage tissue of the almost same appearance as that of original normal
10 outside cartilage tissue (right side) are produced newly (left side) if the composition of the present invention is applied (Figure 3b), although the cellular density is greater than that of original normal cartilage tissues. On the other hand, if only the polymer is applied (Figure 3a), the shape of cells is rough compared to that of normal cells and the density is shown to be low.

15 Accordingly, it is seen that the composition of the present invention is able to produce cartilage tissue in the damaged region of articular cartilage with a superior efficiency and to treat the articular cartilage damage effectively.

In conclusion, the composition for the treatment of articular cartilage damage of the present invention shows excellent effects in histologic aspects for the
20 treatment of the cartilage damage. Compared to the conventional methods of treatment of the articular cartilage damage, the method of its treatment using the composition of the present invention is able to reduce the time, efforts, and expenses for the treatment of articular cartilage damage since the subject method has an effect of sufficiently repairing the articular cartilage damage by employing simple
25 procedures such as the arthroscopic operation or much simpler operation.

While the invention has been described in terms of a single preferred embodiment, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims.

What is claimed is:

1. A composition for the treatment of articular cartilage damage or loss or defect consisting of cellular components separated, proliferated, and/or differentiated
5 from the umbilical cord blood and their culture media.
2. The composition for the treatment of articular cartilage damage or loss or defect of claim 1 characterized by that said cellular components are one or more cellular components that are the umbilical cord blood-derived mesenchymal stem
10 cells, mesenchymal stem/progenitor cells, precursor cells originated from the umbilical cord blood-derived mesenchymal stem/progenitor cells, and chondrocytes or osteocytes differentiated from said mesenchymal stem/progenitor cells.
3. The composition for the treatment of articular cartilage damage of any of
15 claims 1 and 2 characterized by that 1×10^6 to 5×10^7 cellular components are contained in 1 ml of said composition finally.
4. A composition for the treatment of articular cartilage damage or loss or defect consisting of cellular components separated, proliferated, and/or differentiated
20 from the umbilical cord blood, their media, and biocompatible polymers.
5. The composition for the treatment of articular cartilage damage of claim 4 characterized by that said cellular components are one or more cellular components selected from umbilical cord blood, such as mesenchymal stem cells, precursor cells
25 that are originated from said mesenchymal stem cells and may be differentiated into

chondrocytes or osteoblasts, and chondrocytes or osteoblasts differentiated from said mesenchymal stem cells.

6. The composition for the treatment of articular cartilage damage of claim
5 5 characterized by that said biocompatible polymers are polymers having one or
more characteristics among the biocompatibility, biodegradation property and
possible ability to serve to enhance nutrition of cells and possible ability to enhance
formation of intercellular substrate.

10 7. The composition for the treatment of articular cartilage damage of claim
6 characterized by that said biocompatible polymers are consisted of one or more
components selected from natural polymers such as proteins, polysaccharides, etc.;
synthetic polymers comprised of hydroxy acids or their derivatives; and organic
polymers forming the 3-dimensional lattice structure according to chemical binding
15 and their derivatives and transformed compounds.

8. The composition for the treatment of articular cartilage damage of claim
7 characterized by that said biocompatible polymers are consisted of one or more
components selected from fibrin, gelatin, collagen, hyaluronic acid, polyphosphazine,
20 polyacrylate, polyglactic acid, polyglycolic acid, pluronic acid, and alginic acid and
its salts in any shape or configuration.

9. The composition for the treatment of articular cartilage damage of claim
8 characterized by that said biocompatible polymers are those to which any form of
25 the chitosan is added.

10. The composition for the treatment of articular cartilage damage of claim 9 characterized by that said biocompatible polymers are manufactured in such a way that the final content of pluronic acid after it is mixed with cells is 30%.

5

11. The composition for the treatment of articular cartilage damage of claim 9 characterized by that said biocompatible polymers are manufactured in such a way that the final content of hyaluronic acid after it is mixed with cells is 3-4%.

10

12. The composition for the treatment of articular cartilage damage of claim 9 characterized by that said biocompatible polymers are the mixture manufactured in such a way that the final content of pluronic acid after it is mixed with cells is 15-30% and the final content of hyaluronic acid is 2-4%.

15

13. The composition for the treatment of articular cartilage damage of claim 12 characterized by that said biocompatible polymers are manufactured by adding chitosan to said mixture of pluronic acid and hyaluronic acid.


20

14. The composition for the treatment of articular cartilage damage of claims 4 to 13 characterized by that 1×10^6 to 5×10^7 cellular components are contained in 1 ml of said composition finally.


[DRAWING]

[FIG. 1]

a



b




	1	2	3	4	1	2	3	4
Hyaluronic acid	0.5%	1.0%	1.5%	2.0%	0.5%	1.0%	1.5%	2.0%

[FIG. 2]

a



b



[FIG. 3]



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR02/01552

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 A61K 35/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 07 A61K 35/14

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean Patents and applications for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN(CA), PubMed

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NEHRER S. et al., "Chondrocyte-seeded collagen matrices implanted in a chondral defect in a canine model." In Biomaterials, 1998, Vol.19, No.24, p2313-8. See the entire document	1-14
A	FITZPATRICK PL. et al., "Fresh osteochondral allografts: a 6-10-year review." In The Australian and New Zealand journal of surgery, 1998, Vol.68, No.8, p 573-9. See the entire document	1-14
A	US 5902741 A (Advanced Tissue Sciences, Inc.) 11 May 1999 See the entire document	1-14

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	


Date of the actual completion of the international search

03 DECEMBER 2002 (03.12.2002)

Date of mailing of the international search report

04 DECEMBER 2002 (04.12.2002)

Name and mailing address of the ISA/KR

 Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea
Facsimile No. 82-42-472-7140

Authorized officer

KIM, Hee Jin

Telephone No. 82-42-481-5412



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR02/01552

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5902741 A	00.05.1999	JP 62249926 A2 CA 1282725 A1 EP 241578 A2	30.10.1987 09.04.1991 21.10.1987

THIS PAGE LEFT BLANK

COPY FOR IB

PATENT COOPERATION TREATY

PCT



REC'D 13 JAN 2004
WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).	
International application No. PCT/KR02/01552	International filing date (day/month/year) 14 AUGUST 2002 (14.08.2002)	Priority date (day/month/year) 14 AUGUST 2001 (14.08.2001)
International Patent Classification (IPC) or national classification and IPC IPC7 A61K 35/14		
Applicant MEDIPPOST, CO., LTD. et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2.	<p>This REPORT consists of a total of <u>4</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of _____ sheets.</p>
3.	<p>This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input checked="" type="checkbox"/> Certain observations on the international application</p>

Date of submission of the demand 04 MARCH 2003 (04.03.2003)	Date of completion of this report 11 DECEMBER 2003 (11.12.2003)
Name and mailing address of the IPEA/KR  Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea Facsimile No. 82-42-472-7140	Authorized officer KIM, Hee Jin Telephone No. 82-42-481-5412 

THIS PAGE LEFT BLANK

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/KR02/01552

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed
- ☐ the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the claims:
 pages _____, as originally filed
 pages _____, as amended (together with any statement) under Article 19
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the drawings:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language English which is

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☒ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheet _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed," and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

THIS PAGE LEFT BLANK

INTERNATIONAL PRELIMINARY EXAMINATION

International application No.
PCT/KR02/01552

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-14	YES
	Claims	None	NO
Inventive step (IS)	Claims	1-14	YES
	Claims	None	NO
Industrial applicability (IA)	Claims	1-14	YES
	Claims	None	NO

2. Citations and explanations (Rule 70.7)

Reference is made to the following documents from the International Search Report:

D1: Biomaterials, 1998, 19(24), pp. 2313-8

D2: The Australian and New Zealand Journal of Surgery, 1998, 68(8), pp. 573-9

D3: US 5902741 A

The present invention is related to a composition for the treatment of articular cartilage damage composed of cellular components separated, proliferated or differentiated from the umbilical cord blood and their media, or of the above cellular components, their media and biocompatible polymers.

D1 is related to a study to evaluate reparative tissues formed in chondral defects with cultured autologous articular chondrocyte seeded in collagen matrices.

D2 discloses an osteochondral allografts for articular cartilage damage.

D3 relates to a method of stimulating the proliferation and appropriate cell maturation of a variety of different cells including umbilical cord cells and tissues in three-dimensional cultures in vitro using TGF- β in the culture medium.

None of D1-D3 suggest the composition composed of cellular components separated, proliferated or differentiated from the umbilical cord blood. Therefore, the present invention is novel.

The composition for the treatment of articular cartilage damage using cellular components derived from the umbilical cord blood is not obvious to a person skilled in the art. Therefore, the present invention lacks an inventive step.

Claims 1-14 has industrial applicability as a composition for treatment of articular cartilage damage.

THIS PAGE LEFT BLANK

INTERNATIOAL PRELIMINARY EXAMINATION REPORT

International aplication No. .

PCT/KR02/01552

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The wording of "such as" and "etc." in claims 5 and 7 is indefinite, and consequently said claims do not meet the requirements of PCT Article 6.

THIS PAGE LEFT BLANK

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE LEFT BLANK